Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues

Silva, Alexandre G.; Zapata‐Sudo, Gisele; Kümmerle, Arthur Eugen; Fraga, Carlos A.M.; Barreiro, Eliezer J.; Sudo, Roberto T.

doi:10.1016/j.bmc.2005.03.003

Cited by 94 publications

(84 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WO 02/098856] have been previously reported (7). The analytical results for carbon (C), hydrogen (H), and nitrogen (N) for LASSBio-788 were within ± 0.4% of the theoretical values.…”

Section: Methodsmentioning

confidence: 54%

“…In vitro studies have demonstrated that LASSBio-788 exerts relevant antiplatelet activities and reduces phosphodiesterase (PDE) 2 and PDE5 activities (6). Silva et al (7) have demonstrated that LASSBio-788 has relevant vasodilatory properties through the modulation of cyclic nucleotides. LASSBio-788 was rationally designed as a PDE inhibitor and contains the N-acylhydrazone subunit as the pharmacophore group (8 -10).…”

Section: Anti-atherogenic Effects Of a New Thienylacylhydrazone Derivmentioning

confidence: 99%

See 1 more Smart Citation

Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet

et al. 2013

View full text Add to dashboard Cite

Abstract. The compound LASSBio-788 (N-Allyl (2-thienylidene) 3,4-methylenedioxybenzoylhydrazine) is a thienylacylhydrazone derivative shown to have antiplatelet, vasodilatory, and antiinflammatory properties in vitro. We hypothesize that LASSBio-788 may exert beneficial effects on atherosclerosis. Male wistar rats were divided into 4 groups: Control group received standard rat chow, hypercholesterolemic group (HC) and HC+788 (compound LASSBio-788 group) received hypercholesterolemic diet for 45 days. HC+788 group received compound LASSBio-788 (100 mmol/kg) once daily in the last 15 days. LASSBio-788 reduced the levels of total cholesterol (109.1 ± 4.3 vs. 361.0 ± 12.8 mg/dl), triglycerides (66.1 ± 1.1 vs. 186.9 ± 17.7 mg/dl), LDLc (63.2 ± 6.1 vs. 330.9 ± 9.7 mg/dl), VLDLc (9.8 ± 1.1 vs. 45.0 ± 4.6 mg/dl) and malondialdehyde (4.8 ± 0.3 vs. 9.4 ± 0.5 nmol/ml) compared to the HC group. LASSBio-788 presented antiplatelet properties and decreased inflammatory markers levels. LASSBio-788 promoted a decrease in contractile response to phenylephrine and an improvement in endothelium-dependent vasorelaxant response by increasing two-fold the expression of nitric oxide synthase (eNOS). Our results suggest that the compound LASSBio-788 represents a new multi-targeted drug candidate for the treatment of atherosclerosis.

show abstract

“…WO 02/098856] have been previously reported (7). The analytical results for carbon (C), hydrogen (H), and nitrogen (N) for LASSBio-788 were within ± 0.4% of the theoretical values.…”

Section: Methodsmentioning

confidence: 54%

Section: Anti-atherogenic Effects Of a New Thienylacylhydrazone Derivmentioning

confidence: 99%

Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Vasodilation induced by both derivatives is likely to be mediated by a direct effect on smooth muscle because it was not dependent on the integrity of vascular endothelium. LASSBio-785 was seven times more potent than the reference compound LASSBio-294 (IC50 = 74 μM) in producing an endothelium-independent vasodilator effect [72]. …”

Section: Antitumoral Activitymentioning

confidence: 99%

Biological Activities of Hydrazone Derivatives

2007

View full text Add to dashboard Cite

There has been considerable interest in the development of novel compounds with anticonvulsant, antidepressant, analgesic, antiinflammatory, antiplatelet, antimalarial, antimicrobial, antimycobacterial, antitumoral, vasodilator, antiviral and antischistosomiasis activities. Hydrazones possessing an azometine -NHN=CH-proton constitute an important class of compounds for new drug development. Therefore, many researchers have synthesized these compounds as target structures and evaluated their biological activities. These observations have been guiding for the development of new hydrazones that possess varied biological activities.

show abstract

“…Triazolohydrazones possess good antibacterial activity (18). A new bioactive compound of the Nacylhydrazone class, 3,4-methylenedioxybenzoyl-2-thienyl hydrazone, was shown to have inotropic and vasodilatory effects (19). Triaryl hydrazones exhibited antitumoral activity against MCF-7 and ZR-75-1 human malignant breast cell lines (20).…”

Section: Introductionmentioning

confidence: 99%

Activated fly ash-catalyzed synthesis of naphthyl-substituted cyclohexenone carboxylates, indazolonols, and nitro hydrazones in “dry media”

Kanagarajan

Ezhilarasi

Thanusu

et al. 2011

Green Chemistry Letters and Reviews

View full text Add to dashboard Cite

Synthesis and vasodilatory activity of new N-acylhydrazone derivatives, designed as LASSBio-294 analogues

Cited by 94 publications

References 13 publications

Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet

Anti-atherogenic Effects of a New Thienylacylhydrazone Derivative, LASSBio-788, in Rats Fed a Hypercholesterolemic Diet

Biological Activities of Hydrazone Derivatives

Activated fly ash-catalyzed synthesis of naphthyl-substituted cyclohexenone carboxylates, indazolonols, and nitro hydrazones in “dry media”

Contact Info

Product

Resources

About